Determine the necessary mass, volume, or concentration for preparing a solution.
ERα degrader-2 - ≥99% , CAS No.2235396-63-9
Disponibile su ordine
GRADE & PURITY ≥99%
Storage
Store at 2-8°C,Protected from light,Desiccated
Shipped In
Wet ice
224,000+ prodotti di ricerca · Triple ISO certified · COA & SDS Disponibile per ogni prodotto · Spedizione lo stesso giorno su articoli in magazzino
Why this grade
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at 2-8°C,Protected from light,Desiccated Ships Wet ice Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Panoramica
ERα degrader-2 is a selective estrogen receptor degrader ( SERD ) with potent binding affinity with ERα ( IC 50 =17.1 nM), good degradation efficacy ( EC 50 =0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent agentgability, can be used for HER + breast cancer research
In Vitro
ERα degrader-2 (0.01-40 nM) decreases ERα expression and not fully degrades ERα in MCF-7 cells even at a higher biochemical concentration in MCF7 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ERα degrader-2 (oral administration; 2-6 mg/kg; QD; 21 days) leads to the significant tumor growth inhibition and decreases tumor volume in mice . ERα degrader-2 (oral gavage; 2 mg/kg; single dose) possesses better pharmacokinetic properties than AZD9496, the plasma exposure (AUC) is 16073.7 h*ng/mL, and the half-life period is 12.1 h, the oral availability is 80.5% . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MCF-7 human breast cancer xenograft model in nude mice Dosage: 2 mg/kg; 6 mg/kg Administration: Oral administration; 2-6 mg/kg; QD; 21 days Result: Exhibited in vivo efficacy in breast cancer xenograft model.
Form:Solid
IC50& Target:ERα 4.6 nM (IC 50 )
Specifications
Specifiche e purezza
≥99%
Meccanismi biochimici e fisiologici
ERα degrader-2 is a selective estrogen receptor degrader ( SERD ) with potent binding affinity with ERα ( IC 50 =17.1 nM), good degradation efficacy ( EC 50 =0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent agentgability
Condizioni di conservazione di stoccaggio
Store at 2-8°C,Protected from light,Desiccated
Spedito in
Wet ice
Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.
Tipo di azione
INHIBITOR
Purezza
≥99%
Nomi e identificatori
| Peso molecolare | 492.53 |
|---|
Documentazione
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calcolatori di soluzioni
Recensioni
Recensioni dei clienti
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.